Last updated: May 23, 2026
Nicardipine hydrochloride supply is concentrated in a set of branded originators, API manufacturers, and contract manufacturing organizations (CMOs) that produce immediate-release oral solids and injectable formulations. Supplier shortlisting for procurement typically hinges on whether you need API versus drug product (oral vs IV), the jurisdiction (US/EU/India/China), and whether you require DMF/CEP-backed manufacture and sterile fill-finish capability.
What companies supply nicardipine hydrochloride API and finished drug products in 2026?
Primary supply breaks into three layers: API producers, sterile injectable manufacturers (for IV nicardipine), and oral solid manufacturers (for oral controlled-release or immediate-release products, depending on the market).
Which API suppliers are active for nicardipine hydrochloride
Nicardipine hydrochloride API is commonly sourced from specialty generics and API plants in India, China, and parts of Europe. In procurement terms, the key identifiers for qualifying an API supplier are:
- DMF or ASMF status tied to US/EU submissions
- cGMP track record for CEP/EDQM or equivalent documentation
- polymorph/crystal form and stability controls
- validated impurity profile aligned to pharmacopeial and NDA/ANDA specifications
Which finished-dose suppliers matter for nicardipine (oral vs IV)
Nicardipine hydrochloride is marketed as:
- IV nicardipine hydrochloride (critical care setting; requires sterile manufacturing and controlled particle and potency specs)
- oral nicardipine capsules/tablets (hypertension; solid dose plants)
For supplier selection, you typically segregate bids into:
- Sterile injectable CMOs (aseptic fill-finish, endotoxin/sterility testing)
- Solid oral CMOs (tablet/capsule, coating and controlled-release if applicable)
Who makes IV nicardipine hydrochloride injections and who does sterile fill-finish?
IV nicardipine requires sterile GMP manufacturing. Supplier qualification focuses on batch records that cover:
- aseptic processing and sterilizing filtration strategy
- fill-finish line controls (line clearance, container closure integrity)
- in-process controls for concentration uniformity and particle count (where applicable)
- validated hold times and transport conditions for heat-sensitive products
What capacities are typically required from sterile suppliers
A capable supplier generally has:
- dedicated sterile suite or segregated aseptic line
- validated lyophilization or aqueous sterile fill capability depending on product form
- established QC methods for potency, impurities, pH, osmolality (if relevant), and sterility
How do supplier choices differ for US vs EU sterile products?
US procurement usually weights:
- FDA inspections and prior submissions (DMFs tied to ANDAs and supplements)
- readiness for PLAs/labeling and packaging compliance
- ability to support US-specific impurity limits and stability protocols
EU procurement usually weights:
- CEP availability or DMF/ASMF equivalents under EU frameworks
- site GMP status and batch certification workflows under QP release practices
Which suppliers provide oral nicardipine hydrochloride tablets/capsules?
Oral nicardipine hydrochloride supply is typically delivered by solid-dose manufacturers or CMOs that can execute:
- blending and granulation route (wet granulation for certain impurity specs or dry blending for others)
- controlled release technology if the marketed form is extended-release (market dependent)
- robust dissolution testing and in-spec release criteria
What formulation attributes control supplier qualification
Procurement qualification often demands documented control over:
- particle size distribution and compression behavior
- dissolution method alignment to label claims
- stability outcomes for nicardipine hydrochloride under ICH conditions
What are the most common geographic supplier sources for nicardipine hydrochloride?
Supply is most often sourced from:
- India: multiple API and oral sterile/solid-dose plants for generic and hospital products
- China: high-volume API production and generic drug product manufacture
- EU: fewer plants for this niche; often used when CEP/DMF coverage reduces regulatory friction
Procurement practice usually prequalifies suppliers by:
- submission alignment (DMF/ASMF readiness)
- regulatory inspection history
- ability to deliver consistent polymorph and impurity profiles over multiple campaigns
How to shortlist nicardipine hydrochloride suppliers by regulatory readiness (DMF/CEP and inspections)?
A procurement-grade supplier screen for nicardipine hydrochloride usually includes:
- DMF (US) or ASMF (EU) linkage to your target ANDA/variation
- written method compatibility for QC (HPLC/UPLC methods aligned to your spec limits)
- stability program history tied to your target packaging (bottle vs blister, IV container type)
- facility GMP inspection status and any prior 483/Warning Letter relevance
What CMO options exist for nicardipine hydrochloride manufacturing and packaging?
CMOs that can credibly support nicardipine hydrochloride typically split into:
- sterile injectables CMOs (IV nicardipine)
- oral solid-dose CMOs (tablet/capsule and extended-release if required)
- packaging and labeling CMOs (secondary packaging under serialized systems where required)
What contract terms are most important in nicardipine supply contracts
Common contract requirements include:
- change control triggers for API source or synthesis route
- stability data generation responsibilities
- batch release timelines and sterility/fill-finish lead times
- allocation rules during capacity constraints
What generic and biosimilar risk affects nicardipine hydrochloride supply continuity?
Nicardipine hydrochloride is a small-molecule product, so “biosimilar risk” is not applicable. The key supply risk drivers are:
- limited sterile-line capacity for IV products
- API bottlenecks for specific impurity-control routes
- batch failures or slow sterility turnaround in aseptic lines
- patent and exclusivity-driven manufacturing shifts that can strand capacity during transitions
What is the competitive landscape for nicardipine hydrochloride procurement?
Competition typically centers on:
- API price and lead-time competitiveness
- ability to pass regulatory comparability testing (especially for IV)
- quality system maturity and documentation completeness
Procurement tends to favor suppliers that already support:
- sterile injectable filings with compatible compendial methods
- oral solid filings with dissolution method alignment
How many suppliers typically qualify for nicardipine hydrochloride in hospital IV procurement?
In sterile IV procurement, the number of qualifying sources is often smaller than in oral supply because:
- sterile fill-finish capability is rarer
- validation and QC release timelines are longer
- regulatory documentation requirements are higher for injectables
As a result, the supplier pool for IV nicardipine often requires deeper due diligence (audit, method transfer, and stability alignment).
Key Takeaways
- Nicardipine hydrochloride supply splits into API and finished-dose needs: IV sterile injectables versus oral solid forms.
- Shortlist suppliers by DMF/ASMF readiness, cGMP inspection status, and ability to meet impurity and dissolution/sterility specifications.
- For IV nicardipine, sterile fill-finish capacity and release timelines are the dominant constraints.
- Geographic sourcing commonly centers on India and China for API and generic manufacturing, with fewer EU options where CEP/DMF alignment is required.
FAQs
- What documentation should I require from a nicardipine hydrochloride API supplier (DMF/ASMF, COA, impurity profile)?
- Which QC release tests are critical for IV nicardipine hydrochloride injections?
- How do I qualify a new oral nicardipine hydrochloride manufacturer for dissolution and stability?
- What are typical lead-time constraints for sterile fill-finish supply of nicardipine hydrochloride?
- How do changes in API route or supplier impact nicardipine hydrochloride regulatory comparability?
References
(No sources were provided in the prompt, and no cited regulatory or supplier lists were included. No references can be generated without verifiable source material.)
